Loading clinical trials...
Loading clinical trials...
Phase II Study of AZD9291 in Patients With Advanced Stage Non-small Cell Lung Cancer Following Prior EGFR TKI Therapy With EGFR and T790M Mutations Detected in Plasma Circulating Tumor DNA (PLASMA)
Conditions
Interventions
AZD9291
Locations
8
Hong Kong
Pamela Youde Nethersole Eastern Hospital
Chai Wan, Hong Kong
Prince of Wales Hospital
Shatin, Hong Kong
National University Hospital
Singapore, Singapore
Samsung Medical Center Sungkyunkwan University
Irwon-dong, Seoul, South Korea
Yonsei Cancer Center
Sinchon-dong, Seoul, South Korea
Seoul National University College of Medicine
Yeongeon-dong, Seoul, South Korea
Start Date
February 24, 2017
Primary Completion Date
February 24, 2019
Completion Date
February 24, 2020
Last Updated
September 20, 2018
NCT04165798
NCT06667908
NCT06875310
NCT07046923
NCT07222566
NCT06667076
Lead Sponsor
National University Hospital, Singapore
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions